20 (AIDX) Receivables (2024 - 2026)

20's (AIDX) quarterly Receivables came in at $201481.0 in Q1 2026, up 0.76% on a QoQ basis from $199954.0 in Q4 2025.

20 (AIDX) Receivables (2024 - 2026) Analysis & Trends

20 (AIDX) has 3 years of Receivables data on file, last reported at $201481.0 in Q1 2026.

Quarterly Receivables changed N/A year-over-year to $201481.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $201481.0 (changed N/A YoY) and the FY2025 annual result came in at $199954.0, up 47.82% from the prior year.
Receivables rose to $201481.0 in Q1 2026, from $199954.0 in the prior quarter.
In the past five years, Receivables ranged from a high of $201481.0 in Q1 2026 to a low of $135272.0 in Q4 2024.
A 3-year average of $178902.3 and a median of $199954.0 in 2025 frame the typical range for Receivables.
The widest YoY moves for Receivables: up 47.82% in 2025, down 47.82% in 2025.
Tracing AIDX's Receivables over 3 years: stood at $135272.0 in 2024, then surged by 47.82% to $199954.0 in 2025, then gained by 0.76% to $201481.0 in 2026.
The last three Receivables figures came in at $201481.0 (Q1 2026), $199954.0 (Q4 2025), and $135272.0 (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Abbott Laboratories	200.19 Bn	194.59 Bn	7.27 Bn	8.60 Bn
2	Stryker	129.95 Bn	126.47 Bn	4.50 Bn	3.74 Bn
3	Medtronic	120.06 Bn	110.84 Bn	6.41 Bn	6.64 Bn
4	Boston Scientific	74.14 Bn	73.60 Bn	3.85 Bn	3.18 Bn
5	Edwards Lifesciences	52.74 Bn	48.49 Bn	1.35 Bn	955.70 Mn
6	Dexcom	34.60 Bn	32.65 Bn	830.00 Mn	1.28 Bn
7	GE HealthCare Technologies	34.20 Bn	32.10 Bn	2.18 Bn	4.66 Bn
8	Koninklijke Philips	26.46 Bn	23.13 Bn	4.55 Bn	4.12 Bn
9	Steris	23.25 Bn	22.77 Bn	684.20 Mn	1.01 Bn
10	20	5.45 Mn	905,333.06	304,727.00	291,486.00

Download Data